Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability.

Oncotarget - 30 Apr 2015

Scheffler Matthias, Schultheis Anne, Teixido Cristina, Michels Sebastian, Morales-Espinosa Daniela, Viteri Santiago, Hartmann Wolfgang, Merkelbach-Bruse Sabine, Fischer Rieke, Schildhaus Hans-Ulrich, Fassunke Jana, Sebastian Martin, Serke Monika, Kaminsky Britta, Randerath Winfried, Gerigk Ulrich, Ko Yon-Dschun, Krüger Stefan, Schnell Roland, Rothe Achim, Kropf-Sanchen Cornelia, Heukamp Lukas, Rosell Rafael, Büttner Reinhard, Wolf Jürgen

Abstract excerpt

BACKGROUND: While recent data show that crizotinib is highly effective in patients with ROS1 rearrangement, few data is available about the prognostic impact, the predictive value for different treatments, and the genetic heterogeneity of ROS1-positive patients. PATIENTS AND METHODS: 1137 patient...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Rearrangement

Share to Lung Neoplasms

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins

Share to Survival Analysis

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 25868855
DOI: 10.18632/oncotarget.3387
PMCID: PMC4496376

Genes

ROS1
ALK
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25868855-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability.PMID 25868855Read ↗

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.Semantic proximity Read ↗

Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant AlterationsSemantic proximity Read ↗

Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung CancerSemantic proximity Read ↗

<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung CancersSemantic proximity Read ↗

<i><scp>ROS</scp>1</i> expression and translocations in non‐small‐cell lung cancer: clinicopathological analysis of 1478 casesSemantic proximity Read ↗

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to DateSemantic proximity Read ↗

[ROS1-Translocations in Non-Small Cell Lung Cancer].Semantic proximity Read ↗

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted TherapiesSemantic proximity Read ↗

Molecular Changes Associated with Acquired Resistance to Crizotinib in <i>ROS1</i> -Rearranged Non–Small Cell Lung CancerSemantic proximity Read ↗

Different Types of ROS1 Fusion Partners Yield Comparable Efficacy to CrizotinibSemantic proximity Read ↗

Clinicopathologic and molecular characteristics of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients.Semantic proximity Read ↗

Clinical relevance of ROS1 rearrangements detection in advanced squamous cell carcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.